MC2-THERAPEUTICS
MC2 Therapeutics A/S, a late clinical-stage pharmaceutical company focused on topical therapies for chronic inflammatory conditions, today announced the completion of enrollment for its EU Phase 3 study assessing the safety and efficacy of MC2-01 PAD™ Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) in adult patients with plaque psoriasis compared to Daivobet® gel (marketed in the US as Taclonex® Topical Suspension).
“Completion of patient enrollment in this EU Phase 3 registration study marks yet another significant and timely accomplishment for the MC2-01 PAD™ Cream global development program in plaque psoriasis following our successful US Phase 3 head-to-head study in 2018, ” stated Jesper J. Lange, CEO & President of MC2 Therapeutics. He added: “Our efforts in both EU and US demonstrate that we are committed to build leadership in topical therapies for patients with chronic inflammatory conditions. Our proprietary PAD™ Technology enables us to develop a new standard of topical therapies that combine fast and effective relief of symptoms with a unique moisturizing and cosmetic feel that we believe will significantly upgrade the patient experience and convenience in daily routines.”
About the MC2-01 PAD™ Cream Phase 3 Study
The study is a Phase 3, randomized, multicenter, investigator-blind, parallel-group study to evaluate the efficacy and safety of MC2-01 PAD™ Cream in subjects with plaque psoriasis compared to MC2-01 vehicle and Daivobet® gel. Subjects apply study medication topically once daily for up to 8 weeks. The primary objective is to show therapeutic superiority of MC2-01 PAD™ Cream to the active comparator, as well as to characterize the safety profile of MC2-01 PAD™ Cream in subjects with plaque psoriasis. The primary efficacy endpoint is percentage change from baseline in mPASI on the body at Week 8. The study enrolled 490 patients in 32 centres in Europe.
About MC2 Therapeutics A/S
MC2 Therapeutics A/S is a privately held late clinical-stage pharmaceutical company focused on topical therapies for chronic inflammatory conditions. Using its proprietary PAD™ Technology – a unique oil-in-water dispersion – MC2 Therapeutics is developing a pipeline of novel innovative topical therapies designed for unique patient experiences.
For additional information on MC2 Therapeutics Group, please visit www.mc2therapeutics.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190807005489/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zayed Sustainability Prize Honours Global Pioneers Advancing Progress14.1.2026 02:35:00 CET | Press release
US$5.9M awarded to 11 organisations and high schools from the UAE, Brazil, Canada, Nepal, Switzerland, Uganda and across six sustainability categories From AI-enabled diagnostics to Cooling-as-a-Service, this year’s winners deliver locally adapted innovations that empower millions In 18 years, the Prize has scaled solutions reaching more than 411 million people globally The Zayed Sustainability Prize, the UAE’s pioneering award for innovative solutions to global challenges, today announced the cohort of 2026 winners, celebrating 18 years of empowering communities and driving inclusive, sustainable progress around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113958706/en/ The 2026 winners of the Zayed Sustainability Prize were recognised by the President of the UAE in Abu Dhabi on 13 January 2026 (Photo: AETOSWire) In a ceremony held during Abu Dhabi Sustainability Week (ADSW) and attended by Heads of State, M
Alta Semper Secures USD 57.5 Million from EIB Group and IFC for Growth Fund II to Expand Healthcare Access Across Africa13.1.2026 19:30:00 CET | Press release
Alta Semper Capital LLP (“Alta Semper”), a London-based private equity firm focused on healthcare and consumer investments in high-growth markets, today announced that it has secured USD 57.5 million in commitments to Alta Semper Growth Fund II. These commitments come from a consortium of investors including the European Investment Bank (EIB) Group and the International Finance Corporation (IFC). This landmark partnership was signified earlier today with a momentous signing ceremony held at a Government Ministry in Cairo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113837616/en/ Andrew McDowell (EIB), Cheick Oumar Sylla (IFC), Gelsomina Vigliotti (EIB), Rania Al-Mashat (Minister of Planning, Economic Development and International Cooperation of Egypt), Bassel Rahmy (MSMEDA), Afsane Jetha (CEO, Alta Semper) and Mark Bryson-Richardson MBE (British Ambassador to Egypt) at the signing ceremony in Cairo. (Photo: AETOSWire)
500 Global and Creators HQ Support Creators and Founders Building Startups Collectively Valued at US$130M+13.1.2026 17:00:00 CET | Press release
500 Global, one of the world’s most active Silicon Valley-based venture capital firms1, and Creators HQ, the first content creator hub in the UAE and the Middle East enabling the creator ecosystem globally, announced the Creators Ventures Accelerator program is building and supporting creator-led startups collectively valued at over US$130 million.2 The Creators Ventures Accelerator received over 1,100 applications from content creators and technology startup founders across more than 70 countries. Following a competitive selection process, 21 creators and founders were chosen for the program. This cohort serves a community of 20M+ followers, subscribers, and users across platforms. “Creators represent a growing class of bona fide entrepreneurs, with 50 million creators globally, projected to grow at 10-20% annually over the next 5 years. The first iteration of this industry was built on visibility and virality to monetize. With consumers getting savvier and more discerning, we believe
Nexo Becomes First-Ever Title Partner of the U.S. ATP 500 Dallas Open in Multi-Year Deal13.1.2026 16:30:00 CET | Press release
The agreement builds on Nexo’s long-term approach to partnerships with established global sports institutions. Nexo, the digital assets wealth platform, has been named the U.S. ATP 500 Dallas Open’s first-ever Title Partner under a multi-year agreement beginning in 2026, as the company advances its long-term brand strategy through leading global sports properties. The partnership was unveiled in Dallas alongside the debut of the Nexo Dallas Open brand and the resurfacing of two public tennis courts in North Texas. As one of only two ATP 500 tournaments in the U.S. and the country’s sole indoor ATP Tour championship, the Dallas Open places Nexo among a limited group of ATP 500 title partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113901822/en/ The Nexo Dallas Open “This partnership with Nexo represents a transformative milestone for the Dallas Open,” said Tournament Director Peter Lebedevs. “Securing a title spons
Blue Matter Establishes New Capabilities in Biopharma Research & Development Led by Partner, Tara Austraat-Churik13.1.2026 15:01:00 CET | Press release
Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025. Tara Austraat-Churik has been serving life science clients for more than 20 years. Her areas of expertise include strategy development and implementation, operating model and organizational design, and process optimization in R&D and Medical Affairs. Prior to joining Blue Matter, she served as Managing Director in R&D, Health, Science, and Wellness at EY. She has a robust background in consulting, which also includes roles at Booz Allen Hamilton, Navitas, WPP, and IBM. She holds a BA and MA from the University of Notre Dame and an MSc in Translational Medicine from the University of Edinburgh. The R&D practice, according to Austraat-Churik, exists to help biopharma companies simplify and accelerate the pathway to market. She adds, “R&D organ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom